BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 10, 2026
Home » Blogs » BioWorld MedTech Perspectives » Doctoring Twitter; HRS 2015 and social media

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Doctoring Twitter; HRS 2015 and social media

May 18, 2015
By Mark McCarty

Beantown's biggest hosted America's best EPs
Beantown's biggest and America's best EPs

This year’s edition of the Heart Rhythm Society annual scientific sessions is in the can, and there were a number of interesting related developments inside and outside the confines of the Boston Convention and Exhibition Center. While the content was fascinating, there was also a lot about social media that was quite interesting as well.

Lead Twitterators have stethoscopes

Gatherings like HRS draw an interesting and varied crowd, but when you look at the event’s hashtag (#HRS2015), you have to wonder about the ratio of media tweets to those from other sources. It struck me that the event lacked the volume of media coverage that I seem to recall was there in the past. When I dial up the hashtag on my own feed (@MedDeviceMark), it seems that physicians were far and away the heaviest users of the hashtag. Even if you remove the pound sign, media sources account for very few tweets.

The problem – assuming you think this is a problem – is that the media were really not there for the event if the Twitter feed is any indication. There was, however, at least one potentially mitigating circumstance, which I’ll explain later.

Prior engagement over a tech assessment

Conspiracy theory is about as much fun as one can have without breaking the law, and the Centers for Medicare & Medicaid Services released a couple of technology evaluations dealing with cardiac electrophysiology just prior to the HRS festivities in Boston. Coincidence? Maybe, but it’s a lot more fun to think it was timed that way.

The technology evaluation for catheter ablation for treatment of atrial fibrillation is dated April 20, and it shows up at the CMS website 10 days later, so no big deal. However, the tech evaluation for cardiac resynchronization in the Medicare population is dated March 24, and it does not appear on the Medicare coverage center webpage until May 1.

I had tweeted about the ablation/afib document in the first week of May, and a lot of the same electrophysiologists who were active at HRS 2015 were also very active in discussing this document on Twitter. Many of those discussions revolved around patient selection, durability of effect, and which tissues to ablate, all relevant topics.

However, I advised the physicians that CMS has sent a pretty clear signal that it wants to know what it’s paying for, and that the agency will get those data by hook or by crook. David Wilber, the editor in chief of JACC Clinical Electrophysiology seemed to agree, remarking in the May 6 edition of Medical Device Daily that the agency may be trying to tell everyone it’s time for an ablation/afib registry.

As we all know, though, registries ain’t cheap. Medtronic, Boston Scientific and St. Jude Medical should be prepared to bring out the checkbook because hospitals are not going to foot the bill for this one alone, and the National Heart, Lung and Blood Institute doesn’t exactly have access to Fort Knox, either.

The critical question here as best as I can tell is whether CMS will be happy with just a registry, or whether it will start looking at coverage with evidence development for afib ablation in addition to a registry. After all, CMS did announce last year it intends to make more extensive use of CED.

Wireless limbo at BCEC

Anyone in the media who did attend HRS 2015 probably wanted to chew glass over the wireless service at the Boston Convention and Exhibition Center, but calling it “service” is something of a misnomer. It was a nightmare, and it’s difficult to do a lot of tweeting when you’re scrambling to get more basic things done, such as accessing the medical journal articles needed to provide context for our coverage. It wasn't much fun for anyone providing media relations service at HRS, either, and my hat is off to them for working around it.

A note to the head honchos at BCEC. Might wanna get that fixed if you like booking these big, media-friendly conventions.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Infensa Bioscience identifies new ASIC blockers

    BioWorld Science
    Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • Art concept for inflammation in the intestines

    Kymera’s IRF5 degrader shows potential in IBD treatment

    BioWorld Science
    At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing